Viviana Lutzky

Dr. Viviana Lutzky


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
Simon H ApteSimon H Apte
Simon H Apte
PGPenny Groves
Penny Groves
MTMaxine Tan
Maxine Tan
VLViviana Lutzky
Viviana Lutzky
TSTharushi Ayanthika de Silva
Tharushi Ayanthika de Silva
DCDaniel C Chambers
Daniel C Chambers
Idiopathic pulmonary fibrosis (IPF) is the most common and lethal form of the interstitial pneumonias. The cause of the disease is unknown, and new therapies that stop or reverse disease progression are desperately needed. Recent advances in next-generation sequencing have led to an abundance of freely available, clinically relevant, organ-and-disease-specific, single-cell transcriptomic data, including studies from patients with IPF. We mined data from published IPF data sets and identified gene signatures delineating pro-fibrotic or antifibrotic macrophages and then used the Enrichr platform to identify compounds with the potential to drive the macrophages toward the antifibrotic transcriptotype. We then began testing these compounds in a novel in vitro phenotypic drug screening assay utilising human lung macrophages recovered from whole-lung lavage of patients with silicosis. As predicted by the Enrichr tool, glitazones potently modulated macrophage gene expression towards the antifibrotic phenotype. Next, we assayed a subset of the NatureBank pure compound library and identified the cyclobutane lignan, endiandrin A, which was isolated from the roots of the endemic Australian rainforest plant, Endiandra anthropophagorum, with a similar antifibrotic potential to the glitazones. These methods open new avenues of exploration to find treatments for lung fibrosis.

Verified
Journal Article
Open access
PDF file
PGPenny Groves
Penny Groves
LHLevi Hockey
Levi Hockey
BOBrendan O'Sullivan
Brendan O'Sullivan
LZLai-Ying Zhang
Lai-Ying Zhang
ZXZherui Xiong
Zherui Xiong
Simon H ApteSimon H Apte
Simon H Apte
Alveolar macrophages (AM) must perform three seemingly opposing roles including homeostasis, driving inflammation, and facilitating tissue repair. Whilst there is now consensus (supported by a large body of human single cell RNA sequencing (scRNA-seq) data) that the cell subsets that perform these tasks can readily be found based on their transcriptome, their ontogeny has remained unclear. Moreover, there is agreement that in all types of pulmonary fibrosis (PF) there is an expanded population of profibrotic AM that may aberrantly drive PF. From a therapeutic viewpoint, there is great appeal in the notion that the transcriptional program in different AM subsets is not fixed but remains plastic and amenable to pharmacological reprogramming. Accordingly, this study addresses this question by performing scRNA-seq on human AM following treatment with drugs or perturbagens including pioglitazone, trametinib, nintedanib, lipopolysaccharide and the natural compound endiandrin A. Each treatment induced a unique global transcriptional change, driving the cells towards distinct subsets, further supported by trajectory analysis, confirming a high level of plasticity. Confirmatory experiments using qPCR demonstrated that single exposure to a compound induced a relatively stable transcriptome, whereas serial exposure to a different compound allowed the cells to be reprogrammed yet again to a different phenotype. These findings add new insight into the biology of AM and support the development of novel therapies to treat PF.

8 April 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
PGPenny Groves
Penny Groves
LHLevi Hockey
Levi Hockey
BOBrendan O'Sullivan
Brendan O'Sullivan
LZLai-Ying Zhang
Lai-Ying Zhang
ZXZherui Xiong
Zherui Xiong
Simon H ApteSimon H Apte
Simon H Apte
Alveolar macrophages (AM) must perform three seemingly opposing roles including homeostasis, driving inflammation, and facilitating tissue repair. Whilst there is now consensus (supported by a large body of human single cell RNA sequencing (scRNA-seq) data) that the cell subsets that perform these tasks can readily be found based on their transcriptome, their ontogeny has remained unclear. Moreover, there is agreement that in all types of pulmonary fibrosis (PF) there is an expanded population of profibrotic AM that may aberrantly drive PF. From a therapeutic viewpoint, there is great appeal in the notion that the transcriptional program in different AM subsets is not fixed but remains plastic and amenable to pharmacological reprogramming. Accordingly, this study addresses this question by performing scRNA-seq on human AM following treatment with drugs or perturbagens including pioglitazone, trametinib, nintedanib, lipopolysaccharide and the natural compound endiandrin A. Each treatment induced a unique global transcriptional change, driving the cells towards distinct subsets, further supported by trajectory analysis, confirming a high level of plasticity. Confirmatory experiments using qPCR demonstrated that single exposure to a compound induced a relatively stable transcriptome, whereas serial exposure to a different compound allowed the cells to be reprogrammed yet again to a different phenotype. These findings add new insight into the biology of AM and support the development of novel therapies to treat PF.

9 April 2026 in Cells
Verified
Journal Article
Open access
PDF file
Simon H ApteSimon H Apte
Simon H Apte
VLViviana Lutzky
Viviana Lutzky
PGPenny Groves
Penny Groves
DCDan C Chambers
Dan C Chambers
Idiopathic pulmonary fibrosis (IPF) is characterised by progressive parenchymal remodelling, driven by epithelial dysfunction, fibroblast activation, and altered immune regulation within the distal lung. Alveolar macrophages (AMs) reside in a surfactant-rich environment and are specialised for continuous lipid handling, yet the significance of this metabolic role for macrophage heterogeneity and fibrotic progression has remained incompletely integrated across studies. In this review, we synthesise evidence from human lung tissue, experimental models, lipidomic analyses, and clinical investigations to place macrophage populations described in IPF—including FABP4-high homeostatic cells and SPP1-associated disease-enriched states—within a unified lipid-metabolic context. We show that macrophage heterogeneity in IPF can be understood as a variation within a core lipid-handling programme rather than the emergence of distinct macrophage lineages. Profibrotic macrophage states are characterised by altered lipid processing and signalling, including dysregulated sterol handling, lysophospholipid pathways, and eicosanoid balance, which impair surfactant turnover and contribute to fibroblast activation. Importantly, experimental and clinical data indicate that macrophage lipid-metabolic programmes remain modifiable, although definitive disease-modifying efficacy in IPF has yet to be established. Framing macrophage states within a lipid-metabolic framework provides a coherent basis for interpreting heterogeneous datasets and supports the rationale for therapeutic strategies aimed at stabilising or restoring macrophage lipid handling in fibrotic lung disease.

Verified
Journal Article
Open access
PDF file
YSYomani Dilukshi Sarathkumara
Yomani Dilukshi Sarathkumara
KKKiara Knuckey
Kiara Knuckey
VLViviana Lutzky
Viviana Lutzky
PGPenny Groves
Penny Groves
MTMaxine Tan
Maxine Tan
Simon H ApteSimon H Apte
Simon H Apte
Idiopathic pulmonary fibrosis (IPF) is a progressive interstitial lung disease with uncertain etiology. Chronic viral infection, including Epstein–Barr virus (EBV), has been implicated as a potential driver of repetitive epithelial injury and dysregulated repair. We sought to evaluate and define the breadth versus specificity of EBV-directed humoral immunity in IPF. We performed proteome-scale serological profiling using an EBV protein microarray (202 proteins) representing all proteins expressed by the EBV proteome (type I and II) on plasma samples from 32 patients with confirmed IPF (87.5% male; mean age 60.9 years) and 15 healthy disease-free controls (40% male; mean age 57.9 years). Per-sample global EBV IgG means were higher in IPF than controls (Welch p = 0.005), and the difference persisted after sex adjustment (p = 0.012). Although no single antigen met a stringent FDR significance threshold, 10 EBV antigen-specific antibody responses showed nominal elevation in IPF, with 2 remaining nominally significant after sex adjustment and 5 additional antibody responses reaching significance only in linear regression models. Overall, these results support the concept that IPF is associated with a diffuse elevation of EBV-directed humoral responses rather than antigen-specific dominance, consistent with ongoing, low-level viral reactivation. The presence of an EBV-negative subgroup within the IPF cohort underscores etiological heterogeneity within IPF.

24 September 2026 in Biomolecules
Verified
Journal Article
Open access
PDF file
KKKiara Knuckey
Kiara Knuckey
STSjane Timmins
Sjane Timmins
APAmy Pham
Amy Pham
MTMaxine Tan
Maxine Tan
PGPenny Groves
Penny Groves
Simon H ApteSimon H Apte
Simon H Apte
Repeated molecular sampling of the distal airways is constrained by the invasive nature of bronchoalveolar lavage (BAL), limiting its use in healthy control populations, longitudinal studies, clinical trials and occupational screening. Particles in exhaled air (PExA) sampling offers a non-invasive approach to distal-airway sampling, although whether it captures the same proteins and relative protein abundance as BAL has not been established. We performed the first proof-of-principle high-dimensional proteomic comparison of matched BAL and PExA samples collected from three individuals with silicosis using the SomaScan 11K platform. Within individuals, PExA and BAL shared a substantial subset of detectable proteins and showed similar cross-protein signal patterns, with Pearson correlation coefficients ranging from 0.48 to 0.71. Analytes recurrently detected across all three PExA samples were strongly enriched among those consistently detected in BAL and included pulmonary surfactant proteins and mediators associated with epithelial injury, alveolar macrophage function, inflammation and fibrosis. The PExA findings also showed substantial overlap with an independent published PExA-only proteomic dataset. These proof-of-principle findings show that non-invasive PExA sampling can capture a biologically meaningful subset of the matched BAL proteome. PExA may therefore offer a practical approach for repeated molecular profiling of the distal airways and warrants further evaluation for respiratory biomarker discovery and disease monitoring.